Fecal transplants for autism deliver success in clinical trials
328 points
• 3 days ago
• Article
Link
Arizona State University 的研究显示，粪便微生物移植可以在长期内显著缓解儿童自闭症的症状。研究对 18 名接受治疗的自闭症儿童进行了为期两年的随访，发现与基线相比，症状平均减少了 45% 。治疗方案先进行肠道清洁，然后连续七到八周每日进行粪便移植；这些改善不仅持续存在，且随时间进一步加深。治疗前有 83% 的参与者被评为重度自闭症，两年后仅剩 17%，有 44% 已低于轻度自闭症谱系障碍的阈值。
肠道健康与自闭症之间的关联越来越受关注，约有 30% 至 50% 的自闭症人群存在慢性胃肠道问题，如便秘、腹泻和腹痛。研究人员发现，自闭症儿童的肠道微生物多样性明显低于典型发育儿童，缺少若干重要的有益菌株；当这些胃肠道问题得到改善时，儿童的行为和自闭症相关症状也出现了显著好转。
该研究延续了 2017 年的早期工作，后者首次在自闭症儿童中试用粪便移植，并观察到行为、社交能力、多动和沟通方面的改善。尽管最初的益处在八周时已显现（心理自闭症症状下降约 24%），但后续两年的随访表明疗效还在继续增长，降幅达 45% 。
在这些积极结果的推动下，团队为一种名为 Microbiota Transplant Therapy 的特定菌群制剂申请了专利，并成立了商业公司 Gut-Brain Axis Therapeutics 。该疗法已在成人中完成了 2 期安慰剂对照临床试验，与安慰剂组相比，在自闭症症状、胃肠道问题和接受性语言方面均显示出统计学显著的改善。团队目前正寻求资金开展规模更大的 3 期试验，以争取 FDA 的批准。
研究者强调肠道微生物与大脑信号之间的密切联系，指出肠道微生物组在整体健康与神经功能中发挥重要作用。这项工作为将肠道微生物组与抑郁症、创伤后应激障碍、自身免疫疾病等多种疾病联系起来的研究添加了新的证据，提示通过调控肠道健康可能为缓解自闭症症状提供一种新的治疗思路，但仍需更大规模的临床试验来验证结果并获得监管批准。
Research from Arizona State University has demonstrated that fecal microbiota transplants can significantly reduce autism symptoms in children over the long term. The study, which followed 18 autistic children for two years after treatment, found that symptoms decreased by 45 percent compared to baseline. The treatment involved a bowel cleanse followed by daily fecal transplants over seven to eight weeks, and the improvements not only persisted but actually increased over time. Before the treatment, 83 percent of participants were classified as having severe autism, but two years later only 17 percent remained in that category, with 44 percent falling below the threshold for mild autism spectrum disorder.
The connection between gut health and autism has been a growing area of scientific interest, with around 30 to 50 percent of people with autism experiencing chronic gastrointestinal issues like constipation, diarrhea, and stomach pain. The ASU researchers found that children with autism had far lower diversity of gut microbes compared to typically developing children, lacking important beneficial bacteria. When these gastrointestinal problems were treated, the children's behavior and autism-related symptoms showed marked improvement.
The research built on earlier work from 2017 that first introduced fecal transplants to autistic children and observed improvements in behavior, social skills, hyperactivity, and communication. While those initial benefits held for eight weeks, the follow-up study revealed even more impressive long-term outcomes. Doctors observed a 24 percent decrease in psychological autism symptoms at the eight-week mark, which grew to a 45 percent reduction after two years.
Following these promising results, the research team patented a specific bacterial formulation called Microbiota Transplant Therapy and spun off a commercial company called Gut-Brain Axis Therapeutics. The therapy has since moved through Phase 2 placebo-controlled clinical trials with adults, showing statistically significant improvements in autism symptoms, gastrointestinal issues, and receptive language compared to placebo groups. The team is now seeking funding to conduct the large-scale Phase 3 trials necessary for FDA approval.
The researchers emphasize the strong connection between intestinal microbes and brain signals, noting that the gut microbiome plays a crucial role in overall health and neurological function. This work adds to a growing body of research linking the gut microbiome to various conditions including depression, PTSD, and autoimmune disease. The findings suggest that targeting gut health could offer a new therapeutic approach for managing autism symptoms, though larger trials are still needed to confirm the results and gain regulatory approval.
233 comments • Comments Link
有关"减轻自闭症症状"的标题容易产生误导。研究表明，治疗自闭症儿童常见的慢性胃肠道问题可以改善行为表现，这可能只是由于身体不适减轻后，他们更容易掩饰自闭症特征。掩饰通常是无意识的社会化反应，而不是治愈。
许多自闭症儿童饮食极为单一（例如多年只吃一种食物），这会导致营养缺乏（如坏血病），并严重削弱肠道微生物群的多样性。粪便微生物群移植（FMT）或许能在饮食范围扩展后帮助恢复微生物多样性，通过重新引入能够分解新食物的菌种改善状况。
关于到底是微生物群驱动了行为改变，还是饮食塑造了微生物群，存在争议。有人主张肠道细菌会影响渴望或情绪，但更简单的解释是，食物摄入直接决定哪些细菌能繁盛。相关性并不等于因果性，许多微生物群研究未能充分控制混杂因素。
2019 年的初步研究缺乏安慰剂对照组，因此难以将治疗效果与自然发育或其他干预区分开来。随后一项有安慰剂对照的试验（N=60）显示，自闭症症状仅有轻微改善（治疗组 9% vs 对照组 4%），而胃肠道症状的改善更明显，表明主要益处可能在消化系统层面，而非神经行为层面。
批评者指出该研究在伦理设计上存在问题。该治疗涉及为期 8 周的每日直肠移植，引发了关于胁迫的担忧，因为自闭症儿童无法真正给予知情同意。安慰剂组仅接受 3 天且为健康儿童，而治疗组则是为期 8 周的自闭症儿童，这种安排可能引入偏差。
公众对用公共资金支持的研究被商业化表示担忧。参与研究的大学人员为该菌株配方申请了专利，并成立了营利公司——Gut-Brain Axis Therapeutics，这引发了将纳税人资助的科研私有化的伦理质疑。尽管此类做法常见，但往往难以为公众带来相应回报。
该文章在 2025 年更新时加入了该公司的公关声明，但并未提供新的同行评审数据，给人更多像是市场宣传而非科学进展的印象。第二阶段试验结果尚未完全公开，更新的时机更符合投资者利益而非科学透明性。
粪便微生物群移植并非新技术，已用于治疗复发性艰难梭菌感染等疾病。然而，移植菌群的长期定植并不容易，饮食、抗生素和免疫反应等因素都会影响成效。发酵食品和膳食纤维有助于肠道微生物健康，但不能替代严重病例所需的 FMT 。
肠脑轴机制非常复杂，涉及营养吸收、迷走神经调节等多种理论，但微生物群直接驱动自闭症行为改变的证据仍属推测。虽然胃肠不适确实可能加重自闭症症状，但声称"治愈"自闭症既言过其实，也缺乏严格证据支持。
讨论还揭示了科学新闻传播的更广泛问题，例如对研究缺乏持续跟进以及把初步发现渲染为突破性成果。维基式的科学文章模型有助于提升长期准确性和背景信息，但当前的激励机制更倾向于追求轰动效应而非细致严谨。
总体而言，讨论对该研究结论持深刻怀疑态度，参与者强调需更严格的方法学、更多伦理考量，以及明确区分"缓解症状"与"治愈自闭症"。肠脑轴是一个有前景的研究方向，但目前证据仍属初步，且常被商业利益夸大；对长期随访和公共资助研究私有化的担忧也应被重视。 • The headline about reducing autism symptoms is misleading. The study shows that treating chronic gastrointestinal issues common in autistic children leads to behavioral improvements, likely because reducing physical stress makes it easier for them to mask their autism. Masking is a subconscious, socially conditioned response, not a cure.
• Many autistic children have extremely limited diets (e.g., eating only one type of food for years), which can cause nutritional deficiencies like scurvy and severely skew the gut microbiome. A fecal transplant may help restore microbial diversity, especially if the diet has since expanded, by reintroducing bacteria capable of digesting new foods.
• There is skepticism about whether the microbiome drives behavior or if diet shapes the microbiome. While some claim gut bacteria can influence cravings or mood, the simplest explanation is that dietary intake directly determines which bacteria thrive. Correlation does not imply causation, and many microbiome studies fail to account for confounding factors.
• The original 2019 study lacked a placebo control group, making it difficult to isolate the treatment's effect from natural development or other therapies. A subsequent placebo-controlled trial (N=60) showed modest improvements in autism symptoms (9% vs. 4% in controls) but more significant GI improvements, suggesting the primary benefit may be digestive rather than neurological.
• Critics argue the study design is ethically questionable. The treatment involved daily rectal transplants for 8 weeks, raising concerns about coercion, as autistic children cannot meaningfully consent. The placebo arm was only 3 days with healthy children, while the treatment arm lasted 8 weeks with autistic children, introducing bias.
• There is concern about the commercialization of publicly funded research. University researchers patented the bacterial formulation and spun off a for-profit company, Gut-Brain Axis Therapeutics, raising ethical questions about privatizing benefits from taxpayer-funded science. While common, this practice often fails to return proportional value to the public.
• The article was updated in 2025 with PR quotes from the company but no new peer-reviewed data, suggesting a marketing push rather than scientific progress. The phase 2 trial results have not been fully published, and the timing of the update aligns with investor interest, not scientific transparency.
• Fecal microbiota transplants (FMT) are not new and are used for conditions like recurrent C. diff. However, long-term engraftment of transplanted microbes is challenging, and factors like diet, antibiotics, and immune response affect success. Fermented foods and fiber may support microbiome health but are not substitutes for FMT in severe cases.
• The gut-brain axis is complex, with theories involving nutrient absorption and vagus nerve modulation, but evidence for microbiome-driven behavioral changes in autism is still speculative. While plausible that GI distress exacerbates autism symptoms, claims of 'curing' autism are overstated and not supported by rigorous evidence.
• The discussion highlights broader issues in science journalism, such as the lack of follow-up on studies and the spread of preliminary findings as breakthroughs. A wiki-style model for scientific articles could improve long-term accuracy and context, but current incentives favor sensationalism over nuance.
The discussion reveals deep skepticism about the study's claims, with participants emphasizing the importance of rigorous methodology, ethical considerations, and the distinction between treating symptoms and curing autism. While the gut-brain axis is a promising area of research, many argue that current evidence is preliminary and often overstated by commercial interests. The conversation also touches on systemic issues in science communication, such as the lack of long-term follow-up and the privatization of publicly funded research.